Magenta Therapeutics (MGTA: NASDAQ) Investor Relations Material

Overview

Magenta Therapeutics, a leader in biotechnology focused on stem cell transplantation, is making significant strides in unlocking the curative potential of stem cell transplant for patients with genetic diseases, autoimmune diseases, and blood cancers. The company's portfolio of product candidates includes MGTA-117, an anti-CD117 antibody with an amanitin payload, which targets both leukemia cells and hematopoietic stem cells (HSCs), and MGTA-45, an anti-human CD45 antibody, which allows for targeting of HSCs, immune cells, and leukemia cells. The innovative company is also making further investments in the development of an ADC-based conditioning program that targets the T-cell receptor, as well as novel conditioning and translation stem cell sciences. Additionally, Magenta Therapeutics is working on its E478 small molecule aryl hydrocarbon receptor antagonist, designed for use in stem cell-based gene therapy and genome editing. Magenta Therapeutics has recently entered into research and clinical collaboration agreements with AVROBIO, Inc. and Beam Therapeutics, Inc. The former is focused on the treatment of lysosomal storage disorders, while the latter will evaluate the potential of MGTA-117 as a conditioning agent for patients with beta-thalassemia and sickle cell disease. Founded in 2015, the company was initially known as HSCTCO Therapeutics, before changing its name to Magenta Therapeutics in 2016. Headquartered in Cambridge, Massachusetts, Magenta Therapeutics is quickly establishing itself as a leader in the biotechnology industry, with its focus on innovative solutions for patients with life-threatening illnesses.